Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
| Revenue (TTM) | $11.56B |
| Gross Profit (TTM) | $3.84B |
| EBITDA | $2.27B |
| Operating Margin | 15.20% |
| Return on Equity | 14.60% |
| Return on Assets | 6.40% |
| Revenue/Share (TTM) | $105.09 |
| Book Value | $68.33 |
| Price-to-Book | 3.44 |
| Price-to-Sales (TTM) | 2.25 |
| EV/Revenue | 2.736 |
| EV/EBITDA | 14.04 |
| Quarterly Earnings Growth (YoY) | 15.00% |
| Quarterly Revenue Growth (YoY) | 10.20% |
| Shares Outstanding | $110.37M |
| Float | $109.81M |
| % Insiders | 0.44% |
| % Institutions | 99.05% |
Volatility is currently contracting
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
SECAUCUS, N.J., Aug. 12, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026 to shareholders of record of Quest Diagnostics common stock on October 6, 2026.
Samples—and a certain stink—are accumulating at Quest Diagnostics thanks to the cyclosporiasis outbreak. “You get used to it.
Quest Diagnostics president and CEO Jim Davis discusses how his company is implementing AI to help its patients on 'The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #ai #artificialintelligence #health #healthcare #technology #medical #patients #doctors #diagnostics #innovation #business #leadership #future #medicine #jimdavis #questdiagnostics
DGX raised its 2026 outlook as testing demand surged, but lower-margin deals and rising project costs could temper the payoff.
Quest Diagnostics' earnings beat, raised 2026 outlook and broad testing demand support momentum, but valuation, debt and margin pressure temper the buy case.
DGX's broad testing demand, payer access, advanced diagnostics and partnerships support 2026 growth as AI and automation target costs.
Largest nationally representative study finds 12% of patients positive for bacterial vaginosis are infected with at least one STI, such as chlamydia or gonorrhea SECAUCUS, N.J., July 30, 2026 /PRNewswire/ -- Women who test positive for bacterial vaginosis (BV) were over three times more likely to also test positive for one or more non-viral sexually transmitted infections (STIs) than women who test negative for BV, according to a new Health Trends® study from Quest Diagnostics (NYSE: DGX) and Hologic, Inc. In the largest national study of its kind, scientists at Quest and Hologic analyzed deidentified aggregated laboratory data from over 1.5 million women across the United States who received molecular testing from Quest between 2022 and 2024.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DGX and any ticker you trade — then tracks every position and per-strategy win rate.
